Atlas Trials

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Clinical trial NCT07126561 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07126561
Sponsor
University of Chicago
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
Start date
2026-11-01
Primary completion
2028-11-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.